Literature DB >> 12633577

Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review.

Johnny Kao1, Michael C Garofalo, Michael T Milano, Steven J Chmura, Jason R Citron, Daniel J Haraf.   

Abstract

The management of locoregionally recurrent or second primary tumors in a previously irradiated head and neck volume presents a challenging clinical problem. Only a small subset of patients are candidates for potentially curative surgery. Chemotherapy alone provides only limited palliation with no long term survivors. Reirradiation, particularly with aggressive concomitant chemotherapy, results in prolonged median survival and long term survival for some patients. The toxicity of reirradiation, while greater than chemotherapy alone or primary irradiation, is lower than expected for the high cumulative radiation doses. The results of reirradiation in recurrent head and neck cancer and the prognostic factors predicting outcome in this patient population are reviewed.

Entities:  

Mesh:

Year:  2003        PMID: 12633577     DOI: 10.1016/s0305-7372(02)00096-8

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  12 in total

1.  Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.

Authors:  L Vormittag; C Lemaire; D Radonjic; G Kornek; E Selzer
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

2.  A Retrospective Evaluation of Clinical Profile of Second Primary Head and Neck Cancer.

Authors:  Paramjeet Kaur; Nupur Bansal; J Vijaya Kumar; Anil Khurana; Ashok Chauhan
Journal:  J Clin Diagn Res       Date:  2016-10-01

3.  Usefulness of cutting needle biopsy in recurrent and advanced staged head and neck malignancies in a palliative setting.

Authors:  G J Ridder; J Pfeiffer
Journal:  Support Care Cancer       Date:  2007-03-21       Impact factor: 3.603

4.  Outcome after re-irradiation of head and neck cancer patients.

Authors:  Nele Platteaux; Piet Dirix; Bianca Vanstraelen; Sandra Nuyts
Journal:  Strahlenther Onkol       Date:  2010-12-22       Impact factor: 3.621

5.  The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.

Authors:  Jean-Claude M Rwigema; Dwight E Heron; Robert L Ferris; Regiane S Andrade; Michael K Gibson; Yong Yang; Cihat Ozhasoglu; Athanassios E Argiris; Jennifer R Grandis; Steven A Burton
Journal:  Am J Clin Oncol       Date:  2011-08       Impact factor: 2.339

Review 6.  A Technical Guide to Palliative Ablation of Recurrent Cancers in the Deep Spaces of the Suprahyoid Neck.

Authors:  Terrence Chi Hong Hui; Ming Yann Lim; Amit Anand Karandikar; Siu Cheng Loke; Uei Pua
Journal:  Semin Intervent Radiol       Date:  2022-06-30       Impact factor: 1.780

7.  Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy.

Authors:  Gideon Y Bachar; Christopher Goh; David P Goldstein; Brian O'Sullivan; Jonathan C Irish
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02       Impact factor: 2.503

8.  Time interval between primary radiotherapy and salvage laryngectomy: a predictor of pharyngocutaneous fistula formation.

Authors:  William J Scotton; I J Nixon; T F Pezier; R Cobb; A Joshi; T Guerrero Urbano; R Oakley; J P Jeannon; R S Simo
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-17       Impact factor: 2.503

Review 9.  Reirradiation of head and neck cancer focusing on hypofractionated stereotactic body radiation therapy.

Authors:  Hideya Yamazaki; Naohiro Kodani; Mikio Ogita; Kengo Sato; Kengo Himei
Journal:  Radiat Oncol       Date:  2011-08-21       Impact factor: 3.481

10.  Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy.

Authors:  V Rudzianskas; A Inciura; E Juozaityte; M Rudzianskiene; R Kubilius; S Vaitkus; M Kaseta; D Adliene
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-10       Impact factor: 2.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.